Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest ...

This collaboration between Sanofi, RadioMedix and Orano Med focuses specifically on the late-stage project, AlphaMedixTM (212Pb-DOTAMTATE), which currently is being evaluated for the treatment of ...

Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded ...

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear ...

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue. Sanofi ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling down on the nuclear medicine craze. Clinical-stage Orano Med—which is ...

Molecular Partners (MOLN) and Orano Med preparing for clinical entry in 2025 “We are very pleased with the results of MP0712, to date. The homogeneous distribution observed through alpha ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

According to deal terms announced Thursday, Sanofi is paying €100 million (about $110 million) to license AlphaMedix, a radiopharmaceutical developed by partners RadioMedix and Orano Med.

“At Orano Med, we are at the forefront of innovation in radioligand therapy and are developing a global industrial platform for the manufacture and distribution of our 212Pb-conjugated drug ...